Ultragenyx Pharmaceutical In holding history
As of Nov. 6, 2026 (UTC)
| June 30, 2025 | 525,464 | $19,105,871 | 0.18% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2025 |
| Sept. 30, 2025 | 1,069,098 | $32,158,463 | 0.29% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 14, 2025 |
| Dec. 31, 2025 | 1,965,084 | $45,196,925 | 0.48% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 17, 2026 |
| March 31, 2026 | 2,191,182 | $45,905,260 | 0.47% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2026 |
| June 30, 2026 | 2,847,936 | $95,092,590 | 0.89% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2026 |
5 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.